These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 8243040)
21. In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations. Jones RN Drugs; 1988; 35 Suppl 7():17-26. PubMed ID: 3265377 [TBL] [Abstract][Full Text] [Related]
22. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains. Paniagua GL; Monroy E; García O; Vaca S Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741 [TBL] [Abstract][Full Text] [Related]
23. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam. Sader HS; Tosin I; Sejas L; Miranda E Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842 [TBL] [Abstract][Full Text] [Related]
24. [In vitro and in vivo activity of a combination of clavulanic acid and amoxicillin against Klebsiella pneumoniae producing extended broad-spectrum betalactamase (CTX-1, SHV-3, SHV-4)]. Migueres ML; Ronco E; Guenounou M; Philippon A Pathol Biol (Paris); 1989 May; 37(5):397-401. PubMed ID: 2674869 [TBL] [Abstract][Full Text] [Related]
25. The susceptibility to amoxycillin/clavulanate of Enterobacteriaceae with plasmid-mediated ampicillin resistance: a twelve-year study of strains in one Spanish hospital. Rubio MC; Gil J; Castillo J; Otal I; Gómez-Lus ML; Rubio E; Sarraseca C; Torrellas A; Gómez-Lus R J Antimicrob Chemother; 1989 Nov; 24 Suppl B():35-40. PubMed ID: 2606818 [TBL] [Abstract][Full Text] [Related]
26. Effect of bovine lactoferrin on the MICs of ampicillin/sulbactam (UNASYN), amoxicillin/clavulanic acid (Augmentin), ticarcillin clavulanate (Timentin), and piperacillin-tazobactam (ZOSYN), against clinical and environmental isolates of motile Aeromonas. WaKabongo M; Stucki ZN; Torbert DP; Olweny J J Am Osteopath Assoc; 2005 Jan; 105(1):25-6. PubMed ID: 15710671 [No Abstract] [Full Text] [Related]
28. Comparison of ampicillin/sulbactam and amoxicillin/clavulanic acid for detection of borderline oxacillin-resistant Staphylococcus aureus. Liu H; Lewis N Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):47-51. PubMed ID: 1563385 [TBL] [Abstract][Full Text] [Related]
29. Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents. Prabhakaran K; Harris EB; Randhawa B; Adams LB; Williams DL; Hastings RC Microbios; 1993; 76(309):251-61. PubMed ID: 8302203 [TBL] [Abstract][Full Text] [Related]
30. Phenomenon of resistance to Augmentin associated with sensitivity to ampicillin: occurrence and explanation. Brumfitt W; Hamilton-Miller JM; Dixson S; Gargan RA; Gooding A J Clin Pathol; 1983 Jun; 36(6):670-3. PubMed ID: 6343436 [TBL] [Abstract][Full Text] [Related]
31. Comparative efficacies of amoxicillin-clavulanic acid and ampicillin-sulbactam against experimental Bacteroides fragilis-Escherichia coli mixed infections. Gisby J; Beale AS Antimicrob Agents Chemother; 1988 Dec; 32(12):1830-3. PubMed ID: 3072924 [TBL] [Abstract][Full Text] [Related]
32. Development of beta-lactamase inhibitors. Sutherland R J Reprod Med; 1990 Mar; 35(3 Suppl):307-12. PubMed ID: 2319512 [TBL] [Abstract][Full Text] [Related]
33. In vitro susceptibility-resistance patterns of bacterial isolates from burn patients to augmentin and timentin. Holder IA; Vanderpool L; Wesselman J J Burn Care Rehabil; 1985; 6(4):331-4. PubMed ID: 3879938 [No Abstract] [Full Text] [Related]
34. In vitro activity of aminopenicillins combined with sulbactam, clavulanic acid, or amdinocillin against bacteria isolated from patients with complicated urinary tract infections. Naber KG; Wittenberger R Rev Infect Dis; 1986; 8 Suppl 5():S604-8. PubMed ID: 3026011 [TBL] [Abstract][Full Text] [Related]
35. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors. Barry AL; Jones RN; Packer RR J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222 [No Abstract] [Full Text] [Related]
36. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. Nomura S; Hanaki H; Nagayama A J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745 [TBL] [Abstract][Full Text] [Related]
37. Beta-lactamase inhibitors from laboratory to clinic. Bush K Clin Microbiol Rev; 1988 Jan; 1(1):109-23. PubMed ID: 3060240 [TBL] [Abstract][Full Text] [Related]
38. Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy. Itokazu GS; Danziger LH Pharmacotherapy; 1991; 11(5):382-414. PubMed ID: 1745624 [TBL] [Abstract][Full Text] [Related]
39. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarhallis. Doern GV Diagn Microbiol Infect Dis; 1991; 14(1):75-7. PubMed ID: 1901536 [TBL] [Abstract][Full Text] [Related]